These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 37792019)
1. Improving sudden cardiac death risk stratification in hypertrophic cardiomyopathy using established clinical variables and genetic information. Amr A; Koelemen J; Reich C; Sedaghat-Hamedani F; Kayvanpour E; Haas J; Frese K; Lehmann D; Katus HA; Frey N; Meder B Clin Res Cardiol; 2024 May; 113(5):728-736. PubMed ID: 37792019 [TBL] [Abstract][Full Text] [Related]
2. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy. Zegkos T; Tziomalos G; Parcharidou D; Ntelios D; Papanastasiou CA; Karagiannidis E; Gossios T; Rouskas P; Katranas S; Paraskevaidis S; Karvounis H; Efthimiadis G Hellenic J Cardiol; 2022; 63():15-21. PubMed ID: 34147674 [TBL] [Abstract][Full Text] [Related]
3. Validation of the Risk Stratification for Sudden Cardiac Death in Chinese Patients With Hypertrophic Cardiomyopathy. Qi W; Pu L; Zhang J; Chen H; Tang Z; Wang J; Han Y; Chen Y Curr Probl Cardiol; 2023 Nov; 48(11):101875. PubMed ID: 37331610 [TBL] [Abstract][Full Text] [Related]
4. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy. Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532 [TBL] [Abstract][Full Text] [Related]
5. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death. Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875 [TBL] [Abstract][Full Text] [Related]
6. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. Maron MS; Rowin EJ; Wessler BS; Mooney PJ; Fatima A; Patel P; Koethe BC; Romashko M; Link MS; Maron BJ JAMA Cardiol; 2019 Jul; 4(7):644-657. PubMed ID: 31116360 [TBL] [Abstract][Full Text] [Related]
7. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826 [TBL] [Abstract][Full Text] [Related]
8. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410 [TBL] [Abstract][Full Text] [Related]
9. [Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients]. Zhu SH; Li Y; Huang W; Jiang H; Li SN; Chen L; Huang S; Yu HS; Xu B Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):404-408. PubMed ID: 28511325 [No Abstract] [Full Text] [Related]
10. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines. Wang J; Yang S; Ma X; Zhao K; Yang K; Yu S; Yin G; Dong Z; Song Y; Cui C; Li J; Wang C; Hao J; Lu M; Chen X; Zhao S Eur Heart J; 2023 Dec; 44(45):4781-4792. PubMed ID: 37795986 [TBL] [Abstract][Full Text] [Related]
11. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy. Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228 [TBL] [Abstract][Full Text] [Related]
12. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). O'Mahony C; Jichi F; Ommen SR; Christiaans I; Arbustini E; Garcia-Pavia P; Cecchi F; Olivotto I; Kitaoka H; Gotsman I; Carr-White G; Mogensen J; Antoniades L; Mohiddin SA; Maurer MS; Tang HC; Geske JB; Siontis KC; Mahmoud KD; Vermeer A; Wilde A; Favalli V; Guttmann OP; Gallego-Delgado M; Dominguez F; Tanini I; Kubo T; Keren A; Bueser T; Waters S; Issa IF; Malcolmson J; Burns T; Sekhri N; Hoeger CW; Omar RZ; Elliott PM Circulation; 2018 Mar; 137(10):1015-1023. PubMed ID: 29191938 [TBL] [Abstract][Full Text] [Related]
13. Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy. Fahmy AS; Rowin EJ; Jaafar N; Chan RH; Rodriguez J; Nakamori S; Ngo LH; Pradella S; Zocchi C; Olivotto I; Manning WJ; Maron M; Nezafat R JACC Cardiovasc Imaging; 2024 Jan; 17(1):16-27. PubMed ID: 37354155 [TBL] [Abstract][Full Text] [Related]
14. Validation of the 2020 AHA/ACC Risk Stratification for Sudden Cardiac Death in Chinese Patients With Hypertrophic Cardiomyopathy. Dong Y; Yang W; Chen C; Ji J; Zheng W; Zhang F; Yang B; Li X; Zhou X Front Cardiovasc Med; 2021; 8():691653. PubMed ID: 34485400 [No Abstract] [Full Text] [Related]
15. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines. Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207 [TBL] [Abstract][Full Text] [Related]
16. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960 [TBL] [Abstract][Full Text] [Related]
17. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy]. Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362 [No Abstract] [Full Text] [Related]
19. The challenge of risk stratification in hypertrophic cardiomyopathy: Clinical, genetic and imaging insights from a quaternary referral centre. Paratz ED; Stub D; Sutherland N; Gutman S; La Gerche A; Mariani J; Taylor A; Ellims A Int J Cardiol; 2024 Jan; 395():131416. PubMed ID: 37802298 [TBL] [Abstract][Full Text] [Related]
20. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy. Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]